Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis Meeting Abstract
| Authors: | Yacoub, A.; Wang, E. S.; Rampal, R. K.; Borate, U.; Kremyanskaya, M.; Ali, H.; Hobbs, G. S.; O'Connell, C.; Assad, A.; Erickson-Viitanen, S.; Zhou, F.; Burn, T. C.; Daver, N. G. |
| Abstract Title: | Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis |
| Meeting Title: | 112th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2021 Apr 10-15/May 17-21 |
| Meeting Location: | Philadelphia, PA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-07-01 |
| Language: | English |
| ACCESSION: | WOS:000680263501318 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2021-CT162 |
| Notes: | Meeting Abstract: CT162 -- Due to Covid 19 pandemic, the conference was held virtually -- Source: Wos |
